Coya Therapeutics 2025 Q2 Earnings Sharp Loss Widens, Revenue Collapses

Coya Therapeutics (COYA) reported its fiscal 2025 Q2 earnings on Aug 12th, 2025. The results fell well short of expectations, with both revenue and net loss figures worsening significantly compared to the prior year. The company’s performance highlights ongoing financial challenges and mixed investor sentiment in the immediate aftermath of the report.

Coya Therapeutics posted a drastic decline in total revenue, which plummeted by 95.2% to $163,616 in Q2 2025 from $3.43 million in the same period a year ago. The decline was driven entirely by a drop in collaboration revenue, the company's sole reported revenue source for the quarter.

The company’s net loss expanded to $-6.09 million in Q2 2025, a 110.8% increase from the $-2.89 million loss in the prior-year period. On a per-share basis, losses deepened to $0.36 from $0.19, reflecting a 89.5% wider loss. The results underscore the company’s continued financial strain and its heavy reliance on external funding and research milestones.

The stock price of Coya Therapeutics edged up 2.51% during the latest trading day but remains under pressure, having dropped 4.67% during the most recent full trading week and edged down 0.00% month-to-date.

The 30-day holding period following the earnings announcement proved a costly strategy for investors, as the stock failed to recover from its initial post-earnings decline. COYA’s price experienced a sharp drop immediately after the announcement and remained in a negative trajectory, failing to show signs of recovery within the 30-day window. This suggests poor short-term performance despite a revenue raise, reinforcing investor caution and signaling that the earnings report did not inspire confidence in the company’s financial outlook or future catalysts.

Coya Therapeutics CEO Arun Swaminathan, Ph.D., expressed cautious optimism about key upcoming regulatory and scientific milestones. He highlighted the anticipated FDA decision on the IND application for COYA 302 in ALS, expected by August 29, 2025, and the company's plans to submit an IND for FTD by year-end. The CEO emphasized the growing data supporting the regulatory T cell enhancement approach, including findings from an investigator-initiated trial in FTD and preclinical results with COYA 303, which are seen as reinforcing the potential of COYA 302 for both ALS and FTD. The tone reflects a strategic readiness to advance clinical development while managing expectations.

The company expects milestone payments of $8.4 million from Dr. Reddy’s Laboratories upon IND acceptance and the first patient dosing in ALS. It also plans to publish longitudinal ALS biomarker data, new proteomics data from a Phase 2 Alzheimer’s trial, and top-line results from FTD and COYA 303 preclinical studies. These milestones are critical for investor sentiment and potential partnership value, though they do not directly address the current earnings challenges.

Additional News

Recent non-earnings-related developments include a surge in Nigerian Air Force operations, with over 1,500 flight hours conducted in the last eight months under Operation Hadin Kai, resulting in the elimination of 592 terrorists in Borno State. In corporate news, Schneider Electric was named the "World’s Most Sustainable Company" by TIME and Statista for the second consecutive year, reinforcing its leadership in energy management and automation. Meanwhile, in Nigeria, Cross River State has expanded its air fleet, procuring two additional aircraft and planning to acquire three more. These developments reflect a broader landscape of security, sustainability, and public service updates across Nigeria and the global pharmaceutical sector.